Apixaban for Extended Treatment of Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-dose regimen, may be an option for the extended treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in patients with venous thromboembolism who had completed 6 to 12 months of anticoagulation therapy and for whom there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy. The study drugs were administered for 12 months. RESULTS: A total of 2486 patients underwent randomization, of whom 2482 were included in the intention-to-treat analyses. Symptomatic recurrent venous thromboembolism or death from venous thromboembolism occurred in 73 of the 829 patients (8.8%) who were receiving placebo, as compared with 14 of the 840 patients (1.7%) who were receiving 2.5 mg of apixaban (a difference of 7.2 percentage points; 95% confidence interval [CI], 5.0 to 9.3) and 14 of the 813 patients (1.7%) who were receiving 5 mg of apixaban (a difference of 7.0 percentage points; 95% CI, 4.9 to 9.1) (P<0.001 for both comparisons). The rates of major bleeding were 0.5% in the placebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group. The rates of clinically relevant nonmajor bleeding were 2.3% in the placebo group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group. The rate of death from any cause was 1.7% in the placebo group, as compared with 0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group. CONCLUSIONS: Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. (Funded by Bristol-Myers Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For the baseline risk of major bleeding, we used data from 2 randomized trials on people with VTE, showing that the risk of major bleeding with placebo during 18 or 24 months of follow-up was as low as 0.5% 306 and as high as 1.5% in 18 months. 259”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“We identified 2 RCTs 306,314 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Two of these agents, rivaroxaban and apixaban, have been studied at a reduced dose: from 20 mg daily to 10 mg daily for rivaroxaban and 5 mg to 2.5 mg twice daily for apixaban. 306,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [306]
Citations
Cites
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
Self-citationApixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationAspirin for Preventing the Recurrence of Venous Thromboembolism
Becattini, C., Agnelli, G., Schenone, A., Eichinger, S., Bucherini, E., Silingardi, M., Bianchi, M., Moia, M., Ageno, W., Vandelli, M. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114238 · Cited by 620
Self-citation
Research works printed but not linked: 1
- Schulman S, 2011, J Thromb Haemost, 9, 22
Cited by
Items 801–900 of 1,000
Moreno‐Fuquen, R., Hurtado-Angulo, M., Arango‐Daraviña, K., Bain, G., & Kennedy, A. R. (2020) · Acta Crystallographica Section E Crystallographic Communications · doi:10.1107/s2056989020013730 · Cited by 5
Advances in the Management of Acute Venous Thromboembolism and New Therapeutic Agents
Stevens, H., McFadyen, J. D., & Chan, N. (2021) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1723953 · Cited by 5
Quel bilan étiologique réaliser au décours d’une EP/TVP ?
Benhamou, Y., Delluc, A., Mauge, L., Fischer, A., & Sanchez, O. (2021) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2019.05.008 · Cited by 5
A case of acute pulmonary embolism with severe haemoptysis
Mao, R. L., Tromeur, C., & Couturaud, F. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.05.011 · Cited by 6
Characteristics of patients receiving extended treatment after incident venous thromboembolism
Albertsen, I. E., Jensen, M., Abdelgawwad, K., Søgaard, M., Larsen, T. B., & Nielsen, P. B. (2021) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13637 · Cited by 4
“supporting the recommendation of extended treatment were published 2013 and 2017, respectively.(9,10) The official guideline, however, was not published until year 2020.”
BackgroundMethodZakai, N. A., Walker, R. F., MacLehose, R. F., Koh, I., Alonso, Á., & Lutsey, P. L. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12575 · Cited by 4
Beinvenenthrombose und Lungenembolie: Diagnostik und Therapie
Bauersachs, R. M. (2022) · Der Internist · doi:10.1007/s00108-022-01349-1 · Cited by 6
Jacobson, J. D., & Weinberg, I. (2020) · Springer eBooks · doi:10.1007/978-3-030-45792-1_11 · Cited by 4
Wenger, N., Sebastian, T., Beer, J. H., Mazzolai, L., Aujesky, D., Hayoz, D., Engelberger, R. P., Korte, W. C., Voci, D., Kucher, N., et al. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.10.006 · Cited by 5
Neue orale direkte Antikoagulanzien: Viele Vorteile, aber offene Fragen
Haas, S. K., & Schellong, S. (2014) · Der Internist · doi:10.1007/s00108-013-3424-3 · Cited by 5
Novel Oral Anticoagulants for the Prevention and Treatment of Thromboembolism
Oliphant, C. S., Jacobs, A. R., Kabra, R., & Das, P. (2013) · Future Cardiology · doi:10.2217/fca.13.76 · Cited by 4
“5 mg twicedaily, apixaban 5 mg twicedaily or pla cebo for 12 months [25].”
BackgroundPerioperative Management of Oral Anticoagulants: A Focus on Target-Specific Oral Anticoagulants
Barnes, G. D., Eagle, K. A., & Froehlich, J. B. (2014) · Hospital Practice · doi:10.3810/hp.2014.08.1118 · Cited by 4
Diagnosis, prognosis and therapeutic management of acute pulmonary embolism
Tapson, V. F. (2016) · Hospital Practice · doi:10.1080/21548331.2016.1210471 · Cited by 5
“extended therapy trials involving apixaban or rivaroxaban, major bleeding rates – the primary safety end point – associated with DOAC administration were not significantly different from placebo [14,43].”
BackgroundA pharmacotherapy review of the novel, oral antithrombotics
Walters, K. J., Meador, A. E., Galdo, J. A., & Ciarrocca, K. N. (2016) · Special Care in Dentistry · doi:10.1111/scd.12207 · Cited by 4
Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding
Thalji, N. K., & Camire, R. M. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000369 · Cited by 4
Hobohm, L., & Lankeit, M. (2021) · Pneumologie · doi:10.1055/a-1029-9937 · Cited by 4
The safety and efficacy of apixaban: where do we stand in 2013?
Brito, F. D. S., Lópes, R. D., & Alexander, J. H. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.799663 · Cited by 4
“We are awaiting for the results of this trial to define the safety and effective use of apixaban in the complete treatment of VTE [20,21].”
BackgroundInfluentialReduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism
Crowther, M. A., & Cuker, A. C. (2017) · New England Journal of Medicine · doi:10.1056/nejme1701628 · Cited by 4
Top practice-changing articles over the last two years
Kaatz, S., & Gage, B. F. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0896-x · Cited by 3
“699–708 [7]”
Diagnose und Behandlung der Lungenembolie: Einsatz neuer oraler Antikoagulanzien (NOAK)
Hecker, M., Mayer, K., & Bauer, P. (2017) · CME · doi:10.1007/s11298-017-5986-1 · Cited by 3
“5 mg (2 x/d) oder 5 mg (2 x/d) im Vergleich zu Placebo vorteilha im Sinne einer Langzeitsekundärprophylaxe ist [2].”
BackgroundTratamiento de la trombosis venosa profunda de extremidades inferiores
Trujillo‐Santos, J. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2020.05.009 · Cited by 10
Palareti, G., Antonucci, E., Bucherini, E., Caronna, A., Chistolini, A., Giorgio, A. D., Giulio, R. D., Falanga, A., Fregoni, V., Garzia, M., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051343 · Cited by 3
Gołąb, A., Plicner, D., Konieczyńska, M., Broniatowska, E., & Undas, A. (2024) · Medicine · doi:10.1097/md.0000000000038697 · Cited by 3
Hoberstorfer, T., Nopp, S., Steiner, D., Deinsberger, J., Schlager, O., Pabinger, I., Weber, B., & Ay, C. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.05.005 · Cited by 3
Oral Anticoagulants in Women: What's the Difference? A Narrative Review
Faioni, E. M., & Scimeca, B. (2025) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296251347938 · Cited by 3
Länger, F. P., Hart, C., Klima, K., Marten, S., Mühlberg, K. S., Pfrepper, C., & Bauersachs, R. M. (2025) · Hämostaseologie · doi:10.1055/a-2645-4927 · Cited by 3
Cavallaro, C., Santini, P., Leoni, L., Mosoni, C., D’Ambrosio, S., Mancinetti, F., Coletta, N., Iorio, M., Porfidia, A., D’Errico, A., et al. (2025) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-025-03182-3 · Cited by 3
“It is also unknown whether DOACs, especially those at reduced dose, may be effectively and safely used in these patients since the studies on reduced-dose DOACs for extended treatment have not included patients with CRT and UEDVT [25–27 ].”
Nouveaux anticoagulants oraux dans le traitement curatif de la maladie thromboembolique veineuse
Bertoletti, L., Lega, J., Moulin, N., Buchmuller, A., Mismetti, P., & Decousus, H. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.06.001 · Cited by 4
The Role of Novel Anticoagulants in the Management of Venous Thromboembolic Disease
Bott‐Kitslaar, D. M., Wysokiński, W. E., & McBane, R. D. (2014) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-014-0326-1 · Cited by 3
Pharmacological management of pulmonary embolism
Gouin, B., Robert‐Ebadi, H., Righini, M., & Blondon, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1268122 · Cited by 3
Strategien zur Antikoagulation bei Patienten mit tiefer Beinvenenthrombose und Lungenarterienembolie
Radke, P. W., & Möckel, M. (2017) · Herz · doi:10.1007/s00059-017-4655-1 · Cited by 3
Antidotbehandling ved bruk av direktevirkende antikoagulasjonsmidler
Rutherford, O.-C. W., König, M. S. S., Risnes, K., Raouf, N., Atar, D., & Ghanima, W. (2018) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.17.0190 · Cited by 3
Rainville, T., Laskine, M., & Durand, M. (2019) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2018-111057 · Cited by 3
Therapeutic Advances in Emergency Cardiology: Acute Pulmonary Embolism
Petriş, A. O., Konstantinides, S., Ţînţ, D., Cimpoesu, D. C., & Pop, C. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000917 · Cited by 3
Shantsila, E., & Lip, G. Y. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-25460-9_3 · Cited by 5
VTE and anticoagulation in menstruating women
Micaily, I., & Bannow, B. S. (2021) · Thrombosis Update · doi:10.1016/j.tru.2021.100088 · Cited by 3
Are outpatient anticoagulation management services the wave of the future (again)?
Bannow, B. S. (2022) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12735 · Cited by 3
Goessmann, H., Schuffenhauer, V., Kandulski, A., Weigand, K., Jung, E. M., Uller, W., Scharf, G., Stroszczynski, C., & Verloh, N. (2022) · Scientific Reports · doi:10.1038/s41598-022-14388-3 · Cited by 3
Park, H., Kang, H., Huang, P., Lo‐Ciganic, W., DeRemer, C. E., Wilson, D. L., & Dietrich, E. A. (2022) · Clinical and Translational Science · doi:10.1111/cts.13433 · Cited by 3
Management of Thromboembolic Disease in Patients with Primary and Metastatic Brain Tumors
Woods, R. R., & Lesser, G. J. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01116-w · Cited by 3
Hemostatic considerations for gender affirming care
Garland, K., Mullins, E. S., Bercovitz, R. S., Rodriguez, V., Connors, J. M., & Sokkary, N. A. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.09.002 · Cited by 7
Laganà, A., Fucci, L., Sorella, S., Santoro, C., & Chistolini, A. (2024) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000001321 · Cited by 3
“…the efficacy of treatment [8]. prophylaxis, the two pivotal studies that led to approval of apixaban 2.5 mg b.i.d. (AMPLIFY-EXT) and rivaroxaban 10 mg daily (EINSTEIN CHOICE) for such indication had a patients’ median age of 56 .4 (cid:4) 15.6 and 58.8 (cid:4) 14.7 years, respectively [9,10].”
InfluentialOsti, N., Racanelli, V., Susca, N., Martinelli, N., & Maino, A. (2024) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2024.101565 · Cited by 3
“Direct oral anticoagulants (DOACs) are widely used to treat venous thromboembolism (VTE) in adult subjects, both in the acute phase of the disease and in the long-term prophylaxis [10,11], but very little is known about efficacy and safety of DOACs in patients with IVCA-associated DVT.”
Jarugula, P., Ajavon‐Hartmann, A., Obianom, O. N., Ludwig, E. A., Crevar, C., Marchisin, D., Wang, Z., Chen, W., He, B., Mitchell, L. G., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3616 · Cited by 3
Anticoagulation after venous thromboembolism: Deciding on the optimal duration
Eichinger, S. (2013) · Hämostaseologie · doi:10.5482/hamo-13-03-0015 · Cited by 3
Pharmacodynamics, pharmacokinetics and clinical efficacy of apixaban in the treatment of thrombosis
Zheng, S. S., Chong, J. J. H., & Chong, B. H. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1164692 · Cited by 3
Vascular Engineering of Blood Coagulation
Goto, S. (2016) · Springer eBooks · doi:10.1007/978-4-431-54801-0_11 · Cited by 3
Browne, C., Lanitis, T., Hamilton, M., Li, X., Horbyluk, R., Mardekian, J., Kongnakorn, T., & Cohen, A. T. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1258365 · Cited by 3
Self-citationGiustozzi, M., Vedovati, M. C., & Agnelli, G. (2018) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000697 · Cited by 3
Self-citationInteraction Between Direct Factor Xa Inhibitors and Digoxin
Sokol, J., Neháj, F., Ivanková, J., & Mokáň, M. (2018) · American Journal of Therapeutics · doi:10.1097/00045391-900000000-98563 · Cited by 3
Fayol, A., Lanéelle, D., Hoffmann, C., Mahé, G., & Mahé, I. (2019) · VASA · doi:10.1024/0301-1526/a000789 · Cited by 3
Extended oral anticoagulation after incident venous thromboembolism – a paradigm shift?
Albertsen, I. E., Piazza, G., Søgaard, M., Nielsen, P. B., & Larsen, T. B. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1755260 · Cited by 3
“While results from both the EINSTEIN-Choice trial and AMPLIFY-Extension trials offer reassurance that both standard and reduced dose rivaroxaban/apixaban are more effective at reducing recurrence risk than aspirin/placebo, transferring these data into clinical practice requires careful patient selection.”
BackgroundInfluentialKrumb, E., & Hermans, C. R. J. R. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12479 · Cited by 3
Place actuelle des anticoagulants oraux directs dans la maladie thromboembolique veineuse
Roffé, A., Guédon, A. F., & Lallmahomed, E. (2021) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2021.06.005 · Cited by 4
Antithrombotika und Antihämorrhagika
Wille, H. (2021) · Springer eBooks · doi:10.1007/978-3-662-63825-5_17 · Cited by 3
Innasimuthu, A. L., Kumar, S., Akter, S., & BORER, J. S. (2013) · Cardiology · doi:10.1159/000353484 · Cited by 3
Treatment and Long-Term Management of Venous Thromboembolism
AlBadri, A., & Spyropoulos, A. C. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2014.06.011 · Cited by 3
Dabigatran for the treatment of venous thromboembolism
Schellong, S. (2015) · Expert Review of Hematology · doi:10.1586/17474086.2015.1052400 · Cited by 3
“In the pooled analysis of RE-COVER and RE-COVER II, using data from the start of oral-only treatment, there was a statistically signifi- cant reduction in MBEs, MBEs/CRBEs and any bleeding events in patients receiving DE compared with those receiving warfarin.”
BackgroundInfluentialLaw, E. H., & Leung, T. S. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s70299 · Cited by 3
“Extended treatment of VTE with DOACs has been studied for treatment durations between 12 and 36 months.(21,22,25) While all of the DOACs demonstrated a statistically significant reduction in recurrent VTE after patients had been on acute treatment for at least 6 months, only dabigatran has been studied against an acti…”
Xuan, D., McBride, S. J., Wastall, P., Porcari, A. R., DiCarlo, L. A., & Boyd, R. A. (2015) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.232 · Cited by 3
Self-citationTreatment of Venous Thromboembolism
Rose, A. E. (2015) · Springer eBooks · doi:10.1007/978-3-319-22602-6_7 · Cited by 3
New anticoagulants in cancer patient treatments
Arobelidze, S., Haddad, A. S., Spiro, T. P., & Daw, H. A. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000404 · Cited by 3
Gong, X., Wang, H., & Yuan, Y. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3610 · Cited by 3
Budget impact analysis of apixaban to treat and prevent venous thromboembolism in Italy
Bellone, M., Virgilio, R. D., & Rienzo, P. D. (2016) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v17i3.1280 · Cited by 4
“53), while the incidence of major bleeding was similar in all three treatment groups [13].”
BackgroundMethodResultInfluentialOyakawa, T., Muraoka, N., Iida, K., & Kusuhara, M. (2017) · Palliative Care Research · doi:10.2512/jspm.12.175 · Cited by 3
Krumme, A. A., Pawar, A. M., Schneeweiß, S., Glynn, R. J., Choudhry, N. K., Kulldorff, M., Ortiz, A. S., Avorn, J., & Gagne, J. J. (2017) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2017-0053 · Cited by 3
Pharmacologic Reversal of Direct Oral Anticoagulants
Farina, N., & Miller, J. T. (2018) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000193 · Cited by 3
Anticoagulation Beyond 3 to 6 Months: What Does the Data Tell Us?
Carman, T. L. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.04.002 · Cited by 3
Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials
McQuillan, C., Gray, A. P., Kearney, A., & Menown, I. B. A. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0716-y · Cited by 3
“Hemmelgarn et al. undertook a large observational study comparing 12,489 patients receiving NOACs (mostly rivaroxaban) vs. 47,036 receiving warfarin for VTE [95].”
ResultInfluentialOutpatient Oral Anticoagulant Therapy
Ansell, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00037-6 · Cited by 4
Antiphospholipid syndrome and challenges with direct oral anticoagulants
Booth, S. W., Burton, K., Hunt, B. J., & Desborough, M. (2020) · British Journal of Hospital Medicine · doi:10.12968/hmed.2020.0080 · Cited by 3
del Molino, F., González, I. M., & Saperas, E. (2015) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2015.02.014 · Cited by 4
The secondary prevention of venous thromboembolism: Towards an individual therapeutic strategy
Elmi, G., Pizzini, A. M., & Silingardi, M. (2018) · Vascular · doi:10.1177/1708538118776896 · Cited by 3
de Jong, L. A., Gout-Zwart, J. J., Stevanović, J., Rila, H., Koops, M., Huisman, M., & Postma, M. J. (2018) · TH Open · doi:10.1055/s-0038-1672185 · Cited by 3
Prevention and Treatment of Venous Thromboembolism
Streiff, M. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-46202-0.00016-9 · Cited by 6
Salihi, S., Perçin, B., Erkengel, H. İ., Özalp, B., Saçlı, H., & Kara, İ. (2021) · Vascular · doi:10.1177/17085381211052207 · Cited by 3
“In the study reported from Wuhan, the median duration from the onset of COVID-19 symptoms to DVT was 21 days (range, 17–24).17 Standard therapy for DVT patients consists of LMWH combined with VKA.18,19 Several direct oral anticoagulants (DOACs) have been used for the acute and extended treatment of systemic VTE.20,21…”
BackgroundLucey, J. M., King, A. E., Hammond, D. A., & Nemecek, B. D. (2019) · ASHP eBooks · doi:10.37573/9781585285525.004 · Cited by 3
Is there a role yet for new direct oral anticoagulants in cancer patients?
Cohen, A. L., Lim, C. S., & Davies, A. H. (2015) · Phlebology The Journal of Venous Disease · doi:10.1177/0268355515604255 · Cited by 3
Self-citationLa recurrencia en la tromboembolia venosa
del Toro‐Cervera, J., & Rodríguez, P. D. (2016) · Revista Clínica Española · doi:10.1016/j.rce.2016.10.010 · Cited by 4
Introduction to the Vascular Medicine Issue of Progress in Cardiovascular Diseases
Kim, E., & Beckman, J. A. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.04.003 · Cited by 4
Akl, E. A., & Kearon, C. (2014) · doi:10.2217/fmeb2013.13.118 · Cited by 3
Treatment of deep vein thrombosis
Lauw, M. N., & Buller, H. R. (2014) · doi:10.2217/fmeb2013.13.98 · Cited by 5
Self-citationTreatment Options for Venous Thromboembolism in Patients Receiving Dialysis
Mavrakanas, T. A. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03410322 · Cited by 3
Serrao, A., Assanto, G. M., Malfona, F., Orellana, G. C., & Chistolini, A. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15775 · Cited by 3
Kumbhani, D. J., Armbruster, A. L., Cheng, R. K., Chrispin, J., Fischer, U., Holbrook, A. M., Joglar, J., & Sevestre, M.-A. (2026) · JACC · doi:10.1016/j.jacc.2026.05.033 · Cited by 2
Villalobos, A., Valle, R., Escribano, J. P., Ortiz, M., Rodríguez, P. D., & Font, C. (2024) · Revista Clínica Española · doi:10.1016/j.rce.2024.09.003 · Cited by 2
New horizons in the pharmacological management of venous thromboembolism
Verstraete, A., Thillo, Q. V., Vanassche, T., & Verhamme, P. B. (2025) · HemaSphere · doi:10.1002/hem3.70143 · Cited by 2
Superdock, M., Moll, S., & Wilson, S. (2025) · The Hematologist · doi:10.1182/hem.v22.4.2025411 · Cited by 2
Practical guide to management after an acute pulmonary embolism
Alikhan, R., Howard, L., Johnson, M., Sweeney, S., Kiely, D. G., & Pepke‐Żaba, J. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-003028 · Cited by 2
Self-citationDelluc, A., Carrier, M., Lauw, M. N., Cuker, A. C., Bertoletti, L., Beyer‐Westendorf, J., Nisio, M. D., Simard, C., Roberge, G., Harrigan, A. M., et al. (2025) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000001388 · Cited by 2
Arifi, M. A., Alshahrani, W. A., Alshehri, A. M., & Yami, M. S. A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020770 · Cited by 2
“Overall, extended therapy with apixaban, especially the 2.5 mg dose, provided strong protection against recurrence with minimal bleeding risk [3].”
InfluentialTaree, N. A., Lee, A., Sivak, A., Rich, R., Zhu, N. Y., Sun, H., & Wu, C. M. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.01.030 · Cited by 2
Current Management of Cerebral Venous Thrombosis
Field, T. S., & Fragata, I. (2026) · Stroke · doi:10.1161/strokeaha.125.051340 · Cited by 2
Brodmann, M. (2013) · Hämostaseologie · doi:10.5482/hamo-13-02-0005 · Cited by 3
Jiménez, D., & Uresandi, F. (2014) · Angiología · doi:10.1016/j.angio.2014.02.003 · Cited by 3
Fabbian, F., Giorgi, A. D., Tiseo, R., Zucchi, B., & Manfredini, R. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s82484 · Cited by 3
Couturaud, F., Fischer, A., Laporte, S., & Sanchez, O. (2019) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2019.05.003 · Cited by 3
Treatment of Acute Venous Thromboembolism
Nair, S. N., Garza, N., George, M., & Kaatz, S. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.03.004 · Cited by 3
Impact of direct oral anticoagulants on evolution of post-thrombotic syndrome
Pino, L. D., Francaviglia, B., Frazzetto, M., Valenti, N., & Capranzano, P. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.08.021 · Cited by 2
Panchal, H., Agashe, A., Sancheti, P. K., Kulkarni, N., & Taur, S. R. (2021) · SAGE Open Medicine · doi:10.1177/20503121211049962 · Cited by 2
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- McMaster University (CA)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 699-708
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139785591
- Cited by
- 1,366
- References
- 19
- Citations by year
- 2026: 70 · 2025: 80 · 2024: 64 · 2023: 68 · 2022: 90 · 2021: 98 · 2020: 101 · 2019: 114 · 2018: 103 · 2017: 89 · 2016: 109 · 2015: 133 · 2014: 141 · 2013: 102
- FWCI
- 81.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Bayer HealthCare
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, venous thromboembolism, long-term anticoagulation, factor Xa inhibitors, recurrent venous thromboembolism, thromboprophylaxis, major bleeding, mortality, dose comparison, oral anticoagulants, clinical equipoise, post-thrombotic syndrome, pulmonary embolism, deep vein thrombosis
- MeSH terms
- Adult, Aged, Creatinine, Double-Blind Method, Female, Fibrinolytic Agents, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Recurrence, Treatment Outcome, Kaplan-Meier Estimate, Venous Thromboembolism, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.